secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089578
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccitech Q2 net loss $23.8M ($0.62 per share); cash $173M extends runway into Q2 2025
--------------------------------------------------------------------------------

- Net loss $23.8M, widened from $18.2M in Q1 2023; revenue $0.3M from AstraZeneca royalties.
- R&D expense $13.5M, up from $9.8M Q1, driven by HBV and SNAPvax IND-enabling studies.
- Cash $173M vs $191.3M at Q1; operating cash burn $17M; expects runway into Q2 2025.
- Final HBV002 data presented at EASL; VTP-300 induced HBsAg reductions; interim Phase 2 data expected H2 2023.
- CMO Dr. Margaret Marshall retired July 2023; will remain as consultant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/0001104659-23-089578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/tm2323324d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer